Nurix Therapeutics, Inc. NRIX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$87.17M-54.7% | -$78.22M-33.6% | -$86.42M-76.5% | -$43.46M+2.4% | -$56.35M-35.7% | ||
| $2.2M-6.6% | $2.12M-16.8% | $2.03M-15.3% | $2.24M-3.8% | $2.35M+14.9% | ||
| $9.4M+7.8% | $9.09M+6.8% | $9.77M+11.6% | $10.39M+17.4% | $8.72M+11.5% | ||
| -$160K— | —— | —— | —— | $0— | ||
| -$461K+85.6% | —— | —— | -$2.68M-5.4% | -$3.21M-245% | ||
| $4.12M-40.6% | $11.04M+22.4% | $6.34M+4.9% | -$7.01M-2.4% | $6.94M+93.1% | ||
| -$1.29M-121% | $1.28M+4.7% | $1.98M+248% | —— | $6.25M+635% | ||
| -$1.25M+87.3% | -$13.58M-2.2% | -$7.89M-4.0% | -$5.68M— | -$9.83M+21.9% | ||
| $1.58M-11.1% | $2.51M+43.2% | $2.97M+69.6% | $2.86M+62.1% | $1.78M-3.5% | ||
| $205K+112% | -$756K+54.2% | -$1.23M+26.6% | -$1.4M+14.3% | -$1.68M-15.2% | ||
| -$71.91M-17.7% | -$67.83M-39.1% | -$57.39M-36.1% | -$63.16M-59.1% | -$61.09M-45.6% | ||
| $1.05M-70.0% | $5.13M+144% | $2.71M+15.5% | $2.68M+38.1% | $3.49M+20.8% | ||
| $133.15M-4.3% | $179.82M+12.7% | $156.19M+40.9% | $142.34M+48.3% | $139.2M+49.4% | ||
| -$123.83M-585% | $346K+100% | $50.48M+337% | $71.5M+155% | $25.53M-28.1% | ||
| $18M— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $19.98M+1,256% | $236.01M+17.7% | $1.16M-97.5% | $6K-100.0% | $1.47M-9.3% | ||
| -$175.77M-416% | $168.52M+1,439% | -$5.76M— | $8.34M-87.5% | -$34.08M-608% | ||
| $1.98M-44.4% | $1.87M-46.6% | $2.2M-40.7% | $2.7M+25.1% | $3.56M+84.3% | ||
| -$160K— | —— | —— | —— | $0— | ||
| $205K+112% | -$756K+54.2% | -$1.23M+26.6% | -$1.4M+14.3% | -$1.68M-15.2% | ||
| $4.12M-40.6% | $11.04M+22.4% | $6.34M+4.9% | -$7.01M-2.4% | $6.94M+93.1% | ||
| -$1.29M-121% | $1.28M+4.7% | $1.98M+248% | —— | $6.25M+635% | ||
| $1.58M-11.1% | $2.51M+43.2% | $2.97M+69.6% | $2.86M+62.1% | $1.78M-3.5% | ||
| $133.15M-4.3% | $179.82M+12.7% | —— | —— | $139.2M+49.4% | ||
| $1.6M+27.5% | —— | $977K+13.2% | —— | $1.25M-1.3% | ||
| $1.7M+42.2% | —— | $1.04M— | —— | $1.2M+39.9% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $205K+112% | -$756K+54.2% | -$1.23M+26.6% | -$1.4M+14.3% | -$1.68M-15.2% | ||
| —— | $92.75K— | $92.75K— | $92.75K— | $92.75K— | ||
| $2.72M— | $0-100% | $5.79M— | $26.71M— | $0— | ||
| -$72.96M-13.0% | -$72.96M-43.5% | -$60.1M-35.0% | -$65.84M-58.1% | -$64.57M-44.0% | ||
| -$72.96M-13.0% | -$72.96M-43.5% | -$60.1M-35.0% | -$65.84M-58.1% | -$64.57M-44.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Nurix Therapeutics, Inc. generate?
- Nurix Therapeutics, Inc. (NRIX) generated -$260.3M in operating cash flow over the trailing twelve months.
- What is Nurix Therapeutics, Inc.'s free cash flow?
- After $11.6M of capital expenditures, Nurix Therapeutics, Inc.'s free cash flow was -$271.9M over the trailing twelve months, down 34.8% year over year.
- Where does Nurix Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
